If chronic depressive patients choose their treatment... Psychoanalytic and cognitive-behavioural long-term treatment for chronic depression

Psychoanalytic and cognitive-behavioural long-term treatment for chronic depression: short- and long-term effects of preferential treatment and randomised allocation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN91956346

Enrollment

240

Registered

2009-07-10

Start date

2007-06-01

Completion date

Unknown

Last updated

2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic major depression in outpatient care Mental and Behavioural Disorders Depressive episode

Interventions

Arm 1: Preferential treatment. The participants in this arm will choose either psychoanalytic treatment or cognitive-behavioural treatment. Arm 2: Randomised allocation. The participants in this arm w

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Both males and females, age range 21 - 60 years 2. Major depression (by SKID I, the German version of Structural Clinical Interview I [SCID I]) and/or dysthymia (by SKID I) 3. Complaints for at least 12 month 4. Quick Inventory of Depressive Symptomatology - clinician rating (QIDS-C) greater than 9 5. Beck Depression Inventory II (BDI II) greater than 17 6. Sufficent knowlege of the German language 7. No restriction of intellectual capacity 8. Consent to the study protocol, secrecy containment to the treating physician

Exclusion criteria

Exclusion criteria: 1. Current or in the case history psychotic symptomatology, schizoaffective, schizophrenic or bipolar affective disorder 2. Substance dependence current or during the last 3 years 3. Dementia 4. Borderline, schizotypal and antisocial personality disorder 5. Acute suicidality 6. Serious physical illness that strongly affects the depression or is causally for the depression

Design outcomes

Primary

Measure	Time frame
1. Depressive sympomatology, assessed with BDI 2 and QIDS-C at pre- and post-treatment. Treatment response is defined as at least 50% decrease in BDI 2 and QIDS-C scores. 2. Remission, defined as a QIDS-C score of less than 6 3. SKID 4. Operational psychodynamic diagnosis (Operationalisierte Psychodynamische Diagnostik) (OPD2) All primary and secondary outcomes will be assessed at the initial examination (t0) and after 1, 2 and 3 years of treatment.	—

Measure

Time frame

1. Depressive sympomatology, assessed with BDI 2 and QIDS-C at pre- and post-treatment. Treatment response is defined as at least 50% decrease in BDI 2 and QIDS-C scores. 2. Remission, defined as a QIDS-C score of less than 6 3. SKID 4. Operational psychodynamic diagnosis (Operationalisierte Psychodynamische Diagnostik) (OPD2) All primary and secondary outcomes will be assessed at the initial examination (t0) and after 1, 2 and 3 years of treatment.

—

Secondary

Measure	Time frame
1. Symptom Checklist-90-R (SCL-90-R) 2. Social and Occupational Functioning Assessment Scale (SOFAS) 3. Depressive Experiences Questionnaire (DEQ) 4. Reduction in health costs, assessed using health insurance data All primary and secondary outcomes will be assessed at the initial examination (t0) and after 1, 2 and 3 years of treatment.	—

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 25, 2026